For the quarter ending 2025-06-30, CYCCP had $1,138K increase in cash & cash equivalents over the period. -$4,303K in free cash flow.
| Cash Flow | 2025-06-30 |
|---|---|
| Stock-based compensation | 1,673 |
| Net loss | -1,399 |
| Prepaid expenses and other assets | -1,544 |
| Changes in lease liability | 10 |
| Accounts payable, accrued and other current liabilities | -11,079 |
| Depreciation | 1 |
| Deconsolidation of subsidiary | 4,947 |
| Net cash used in operating activities | -4,303 |
| Purchase of property, plant and equipment | 0 |
| Net cash used in investing activities | 0 |
| Proceeds, net of issuance costs, from issuing common stock and pre-funded warrants, net | 5,567 |
| Payment of preferred stock dividend | 41 |
| Proceeds from the exercise of stock options and warrants, net of issuance costs | 0 |
| Net cash provided by (used) in financing activities | 5,526 |
| Effect of exchange rate changes on cash and cash equivalents | -85 |
| Net increase (decrease) in cash and cash equivalents | 1,138 |
Cyclacel Pharmaceuticals, Inc. (CYCCP)
Cyclacel Pharmaceuticals, Inc. (CYCCP)